David M. Goldstein
Chief Scientific OfficerDr. David M. Goldstein Ph.D., serves as Chief Scientific Officer at Alumis, Inc. (also known as Esker Therapeutics) since September 2021 and served as its and Head of CMC. He served as the Chief Scientific Officer since 2016 at Principia Biopharma Inc. and serves as its Site Head since 2020. He served as Vice President of Drug Discovery at Principia Biopharma Inc. Dr. Goldstein held positions of increasing responsibility at Roche, served as Senior Director of Medicinal Chemistry and Head of Inflammation Chemistry (March 2009-February 2011) and its Director (1994-2009). Dr. Goldstein serves as Independent Director of Frontier Medicines Corporation since March 2021. Dr. Goldstein also was previously a Consulting Assistant Professor at Stanford University. He received a B.A. in Chemistry from Franklin and Marshall College and a Ph.D. in Chemistry from the University of Virginia in 1992.
公司職務
- 公司名稱Alumis Inc.股票代碼ALMS職務Chief Scientific Officer共事同僚
- MBMartin BablerPresident, CEO & Chairman
- JDJorn DrappaChief Medical Officer & Head of Research and Development
- JRJohn R. SchroerChief Financial Officer
- SPSanam PangaliChief Legal Officer & Corporate Secretary
- ABAlan B. ColowickIndependent Director
- SSSapna SrivastavaLead Independent Director
- CPC. Patrick MachadoIndependent Director
- JBJames Bruce TananbaumIndependent Director
